Pfizer settles with Teva and Actavis, the last act in Neurontin’s 11-year patent fight
This article was originally published in Scrip
Executive Summary
Pfizer has settled all US patent infringement claims it had against Teva Pharmaceutical Industries and Actavis Group's Purepac unit in a long-running suit over generic versions of the epilepsy drug Neurontin (gabapentin). The settlements were reached during a jury trial that had begun in federal court in mid-May where Pfizer claimed it should be compensated for years of lost sales (in the billions) because of the "at-risk" launch by the firms in 2004.